KRAS and non-small cell lung carcinoma: Results from a retrospective analysis performed in patients with KRAS mutant NSCLC receiving immune checkpoint inhibitors demonstrated a significantly lower response rate (7.4% vs. 35.7%) and shorter progression free survival (PFS) and overall survival (OS) in those patients included in the KL subgroup compared with those in the KP subgroup [25].